Jakarta: Head of the Institute for Molecular Biology (LBM) Eijkman Amin Soebandrio said the developments red and white vaccine currently still in the optimization stage. This stage is the transition process from laboratory to industry for the developed Red and White vaccine seeds.
“Currently, we are in transition from the lab to the industry. We are going back and forth from the lab to the industry,” Amin said when contacted on Wednesday, July 21, 2021.
Eijkman developed red and white vaccine with platform recombinant protein subunits. The vaccine seeds were given to the industry, namely PT Bio Farma.
How do you feel about this article?
–
–
In the optimization stage, Eijkman has placed his researchers at PT Bio Farma to prepare vaccine seeds. At Bio Farma, the vaccine seeds will be cultured.
“The process is currently still in the optimization process so that what is done in the laboratory can then be translated into industry with industrial conditions, of course, it’s different from the laboratory,” he said.
While in the laboratory, researchers work on vaccine seeds on a small scale in small tubes or small bottles while in industry the scale is much larger. Thus, it is still at the stage of optimizing vaccine seed products in industrial bioreactors that require various adjustments.
Read: IPB Students Create Sexual Violence Reporting Applications
The transition process from laboratory to industry takes a long time because it goes through several processes. One of them, upscaling to be able to breed vaccine seeds in large numbers in the industry.
In the laboratory, vaccine seeds are grown in milliliters, for example 100 milliliters. While in the industry, in the amount of tens of liters and maybe hundreds of liters.
“Well, it doesn’t always change automatically, there must be adjustments. We have to look for the best conditions so that the vaccine still meets the requirements of being safe, effective and halal but also having a high enough yield so that it can be produced economically. , that is now being pursued,” said Amin.
Amin hopes that clinical trials of the Merah Putih vaccine can begin in late 2021 or early 2022. Then, they can get an emergency use authorization in mid-2022.
(BUT)
– .
